Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Get in touch

1800 437 222

Viral hepatitis (A, B & C)

Hepatitis means inflammation of the liver, and it can be caused by a virus or other non-viral causes.  The main difference between the viruses is how they are spread and the effects they have on your health.

Read more...

Prevention

There are safe and effective vaccines that protect you from getting hepatitis A and B.  While there is no vaccine for hep C, by being ‘blood aware’ you can reduce your overall chance of being exposed to the virus.

Read more...

Living with Hepatitis

People with chronic hepatitis can do a number of things to stay healthy including limiting/avoiding alcohol, reducing stress, not smoking, getting regular exercise and eating a healthy diet.

Read more...

Treatment

Effective treatment is available for both chronic hepatitis B and C.  Before you can see a liver specialist to talk about going on treatment, you need to get a referral from your GP first.

Read more...
ContentViewArticle Object
(
    [item:protected] => stdClass Object
        (
            [id] => 338
            [asset_id] => 412
            [title] => "Christmas comes early for Australians living with hepatitis C" - Hepatitis Australia
            [alias] => christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia
            [title_alias] => 
            [introtext] => Smiley face
Image credit: Jane Little, in Sydney Morning Herald. Photo: Meredith O'Shea​


====================
UPDATE 22 December 2015: FAQs about the new hepatitis C medicines and the March 2016 PBS Listing
Click here to read the latest questions and answers:
http://www.hepatitisaustralia.com/faq-hep-c-treatments
====================


20 December 2015

LISTED!!!

We are very pleased to be able to share this special breaking news [now featured in Sydney Morning Herald].

We would like to thank each of you for your tremendous support and patience over such a long haul. This could not have happened without you.

There is still a long way to go and a great deal of work to be done but today is a day to remember.

We will continue to keep you updated as more details become available.

Thank you.

Regards
Clint Ferndale
CEO


Hepatitis Australia Media Release
For Immediate Release 20 December 2015

"Christmas comes early for Australians living with hepatitis C"



Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.

Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.

“Last week, we were incredibly disheartened that the Mid-Year Economic and Fiscal Outlook (MYEFO) announcement did not include funding for new hepatitis C medicines, but today we are overjoyed that the waiting is almost over,” Ms Tyrrell said.

“So many people have been anxiously waiting for this announcement. This is wonderful news and it is such a relief to have an end to the uncertainty,” she said.

“We congratulate Minister Ley who has delivered on her commitment to list these medicines as swiftly as she can and to make them available for everyone with hepatitis C, which hasn’t been achieved elsewhere.

“Christmas will be a particularly joyous time this year for many living with hepatitis C as they can now look forward to the prospect of a cure and a much healthier future,” Ms Tyrrell said.

“The Turnbull Government is to be congratulated for showing leadership and investing in these game-changing therapies which represent the greatest innovation in the treatment of the hepatitis C virus in a generation,” she said.

“If we can combine access to new treatments with improved access to needle and syringe programs across the country and in all populations, we have a real chance of preventing deaths and eliminating hepatitis C as a public health concern within a generation.

“We look forward to 2016 as the watershed year for hepatitis C in Australia as more people are treated and cured and we start to arrest spiralling rates of liver disease,” Ms Tyrrell added.

230,500 Australians are living with the hepatitis C virus which damages the liver, leading to liver scarring (cirrhosis), liver cancer and liver failure. Each month approximately 250 people with hepatitis C develop serious and potentially life-threatening liver disease or liver cancer.

New hepatitis C therapies have exceptionally high cure rates that exceed 90 per cent, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies.

“We urge all Australians with risk factors for hepatitis C to get tested and talk to their doctor about new treatments,” Ms Tyrrell concluded.

*sofosbuvir (Sovaldi); sofosbuvir and ledipasvir (Harvoni); daclatasvir (Daklinza) and ribavirin (Ibavyr).

Media Contact: Fiona Beveridge 0405 902 826.


Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-12-20 08:19:39 [created_by] => 66 [created_by_alias] => [modified] => 2015-12-22 05:33:35 [modified_by] => 66 [checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [publish_up] => 2015-12-20 08:19:39 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 15 [parentid] => 0 [ordering] => 71 [metakey] => [metadesc] => [access] => 1 [hits] => 3413 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 338:christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/338-christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [text] => Smiley face
Image credit: Jane Little, in Sydney Morning Herald. Photo: Meredith O'Shea​


====================
UPDATE 22 December 2015: FAQs about the new hepatitis C medicines and the March 2016 PBS Listing
Click here to read the latest questions and answers:
http://www.hepatitisaustralia.com/faq-hep-c-treatments
====================


20 December 2015

LISTED!!!

We are very pleased to be able to share this special breaking news [now featured in Sydney Morning Herald].

We would like to thank each of you for your tremendous support and patience over such a long haul. This could not have happened without you.

There is still a long way to go and a great deal of work to be done but today is a day to remember.

We will continue to keep you updated as more details become available.

Thank you.

Regards
Clint Ferndale
CEO


Hepatitis Australia Media Release
For Immediate Release 20 December 2015

"Christmas comes early for Australians living with hepatitis C"



Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.

Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.

“Last week, we were incredibly disheartened that the Mid-Year Economic and Fiscal Outlook (MYEFO) announcement did not include funding for new hepatitis C medicines, but today we are overjoyed that the waiting is almost over,” Ms Tyrrell said.

“So many people have been anxiously waiting for this announcement. This is wonderful news and it is such a relief to have an end to the uncertainty,” she said.

“We congratulate Minister Ley who has delivered on her commitment to list these medicines as swiftly as she can and to make them available for everyone with hepatitis C, which hasn’t been achieved elsewhere.

“Christmas will be a particularly joyous time this year for many living with hepatitis C as they can now look forward to the prospect of a cure and a much healthier future,” Ms Tyrrell said.

“The Turnbull Government is to be congratulated for showing leadership and investing in these game-changing therapies which represent the greatest innovation in the treatment of the hepatitis C virus in a generation,” she said.

“If we can combine access to new treatments with improved access to needle and syringe programs across the country and in all populations, we have a real chance of preventing deaths and eliminating hepatitis C as a public health concern within a generation.

“We look forward to 2016 as the watershed year for hepatitis C in Australia as more people are treated and cured and we start to arrest spiralling rates of liver disease,” Ms Tyrrell added.

230,500 Australians are living with the hepatitis C virus which damages the liver, leading to liver scarring (cirrhosis), liver cancer and liver failure. Each month approximately 250 people with hepatitis C develop serious and potentially life-threatening liver disease or liver cancer.

New hepatitis C therapies have exceptionally high cure rates that exceed 90 per cent, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies.

“We urge all Australians with risk factors for hepatitis C to get tested and talk to their doctor about new treatments,” Ms Tyrrell concluded.

*sofosbuvir (Sovaldi); sofosbuvir and ledipasvir (Harvoni); daclatasvir (Daklinza) and ribavirin (Ibavyr).

Media Contact: Fiona Beveridge 0405 902 826.


Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) [params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [print:protected] => [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 338 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [user:protected] => JUser Object ( [isRoot:protected] => [id] => 0 [name] => [username] => [email] => [password] => [password_clear] => [usertype] => [block] => [sendEmail] => 0 [registerDate] => [lastvisitDate] => [activation] => [params] => [groups] => Array ( ) [guest] => 1 [lastResetTime] => [resetCount] => [_params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( ) ) [_authGroups:protected] => Array ( [0] => 1 ) [_authLevels:protected] => Array ( [0] => 1 [1] => 1 ) [_authActions:protected] => [_errorMsg:protected] => [_errors:protected] => Array ( ) [aid] => 0 ) [_name:protected] => article [_models:protected] => Array ( [article] => ContentModelArticle Object ( [_context:protected] => com_content.article [_item:protected] => Array ( [338] => stdClass Object ( [id] => 338 [asset_id] => 412 [title] => "Christmas comes early for Australians living with hepatitis C" - Hepatitis Australia [alias] => christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [title_alias] => [introtext] => Smiley face
Image credit: Jane Little, in Sydney Morning Herald. Photo: Meredith O'Shea​


====================
UPDATE 22 December 2015: FAQs about the new hepatitis C medicines and the March 2016 PBS Listing
Click here to read the latest questions and answers:
http://www.hepatitisaustralia.com/faq-hep-c-treatments
====================


20 December 2015

LISTED!!!

We are very pleased to be able to share this special breaking news [now featured in Sydney Morning Herald].

We would like to thank each of you for your tremendous support and patience over such a long haul. This could not have happened without you.

There is still a long way to go and a great deal of work to be done but today is a day to remember.

We will continue to keep you updated as more details become available.

Thank you.

Regards
Clint Ferndale
CEO


Hepatitis Australia Media Release
For Immediate Release 20 December 2015

"Christmas comes early for Australians living with hepatitis C"



Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.

Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.

“Last week, we were incredibly disheartened that the Mid-Year Economic and Fiscal Outlook (MYEFO) announcement did not include funding for new hepatitis C medicines, but today we are overjoyed that the waiting is almost over,” Ms Tyrrell said.

“So many people have been anxiously waiting for this announcement. This is wonderful news and it is such a relief to have an end to the uncertainty,” she said.

“We congratulate Minister Ley who has delivered on her commitment to list these medicines as swiftly as she can and to make them available for everyone with hepatitis C, which hasn’t been achieved elsewhere.

“Christmas will be a particularly joyous time this year for many living with hepatitis C as they can now look forward to the prospect of a cure and a much healthier future,” Ms Tyrrell said.

“The Turnbull Government is to be congratulated for showing leadership and investing in these game-changing therapies which represent the greatest innovation in the treatment of the hepatitis C virus in a generation,” she said.

“If we can combine access to new treatments with improved access to needle and syringe programs across the country and in all populations, we have a real chance of preventing deaths and eliminating hepatitis C as a public health concern within a generation.

“We look forward to 2016 as the watershed year for hepatitis C in Australia as more people are treated and cured and we start to arrest spiralling rates of liver disease,” Ms Tyrrell added.

230,500 Australians are living with the hepatitis C virus which damages the liver, leading to liver scarring (cirrhosis), liver cancer and liver failure. Each month approximately 250 people with hepatitis C develop serious and potentially life-threatening liver disease or liver cancer.

New hepatitis C therapies have exceptionally high cure rates that exceed 90 per cent, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies.

“We urge all Australians with risk factors for hepatitis C to get tested and talk to their doctor about new treatments,” Ms Tyrrell concluded.

*sofosbuvir (Sovaldi); sofosbuvir and ledipasvir (Harvoni); daclatasvir (Daklinza) and ribavirin (Ibavyr).

Media Contact: Fiona Beveridge 0405 902 826.


Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-12-20 08:19:39 [created_by] => 66 [created_by_alias] => [modified] => 2015-12-22 05:33:35 [modified_by] => 66 [checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [publish_up] => 2015-12-20 08:19:39 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 15 [parentid] => 0 [ordering] => 71 [metakey] => [metadesc] => [access] => 1 [hits] => 3413 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 338:christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/338-christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [text] => Smiley face
Image credit: Jane Little, in Sydney Morning Herald. Photo: Meredith O'Shea​


====================
UPDATE 22 December 2015: FAQs about the new hepatitis C medicines and the March 2016 PBS Listing
Click here to read the latest questions and answers:
http://www.hepatitisaustralia.com/faq-hep-c-treatments
====================


20 December 2015

LISTED!!!

We are very pleased to be able to share this special breaking news [now featured in Sydney Morning Herald].

We would like to thank each of you for your tremendous support and patience over such a long haul. This could not have happened without you.

There is still a long way to go and a great deal of work to be done but today is a day to remember.

We will continue to keep you updated as more details become available.

Thank you.

Regards
Clint Ferndale
CEO


Hepatitis Australia Media Release
For Immediate Release 20 December 2015

"Christmas comes early for Australians living with hepatitis C"



Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.

Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.

“Last week, we were incredibly disheartened that the Mid-Year Economic and Fiscal Outlook (MYEFO) announcement did not include funding for new hepatitis C medicines, but today we are overjoyed that the waiting is almost over,” Ms Tyrrell said.

“So many people have been anxiously waiting for this announcement. This is wonderful news and it is such a relief to have an end to the uncertainty,” she said.

“We congratulate Minister Ley who has delivered on her commitment to list these medicines as swiftly as she can and to make them available for everyone with hepatitis C, which hasn’t been achieved elsewhere.

“Christmas will be a particularly joyous time this year for many living with hepatitis C as they can now look forward to the prospect of a cure and a much healthier future,” Ms Tyrrell said.

“The Turnbull Government is to be congratulated for showing leadership and investing in these game-changing therapies which represent the greatest innovation in the treatment of the hepatitis C virus in a generation,” she said.

“If we can combine access to new treatments with improved access to needle and syringe programs across the country and in all populations, we have a real chance of preventing deaths and eliminating hepatitis C as a public health concern within a generation.

“We look forward to 2016 as the watershed year for hepatitis C in Australia as more people are treated and cured and we start to arrest spiralling rates of liver disease,” Ms Tyrrell added.

230,500 Australians are living with the hepatitis C virus which damages the liver, leading to liver scarring (cirrhosis), liver cancer and liver failure. Each month approximately 250 people with hepatitis C develop serious and potentially life-threatening liver disease or liver cancer.

New hepatitis C therapies have exceptionally high cure rates that exceed 90 per cent, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies.

“We urge all Australians with risk factors for hepatitis C to get tested and talk to their doctor about new treatments,” Ms Tyrrell concluded.

*sofosbuvir (Sovaldi); sofosbuvir and ledipasvir (Harvoni); daclatasvir (Daklinza) and ribavirin (Ibavyr).

Media Contact: Fiona Beveridge 0405 902 826.


Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) ) [__state_set:protected] => 1 [_db:protected] => JDatabaseMySQLi Object ( [name] => mysqli [nameQuote:protected] => ` [nullDate:protected] => 0000-00-00 00:00:00 [dbMinimum:protected] => 5.0.4 [_database:JDatabase:private] => hepqld_joomla [connection:protected] => mysqli Object ( [affected_rows] => 1 [client_info] => mysqlnd 5.0.11-dev - 20120503 - $Id: 76b08b24596e12d4553bd41fc93cccd5bac2fe7a $ [client_version] => 50011 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 0 [host_info] => Localhost via UNIX socket [info] => Rows matched: 1 Changed: 1 Warnings: 0 [insert_id] => 0 [server_info] => 5.6.35 [server_version] => 50635 [stat] => Uptime: 2891542 Threads: 1 Questions: 214799284 Slow queries: 211 Opens: 9974280 Flush tables: 1 Open tables: 2000 Queries per second avg: 74.285 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 3820408 [warning_count] => 0 ) [count:protected] => 0 [cursor:protected] => 1 [debug:protected] => [limit:protected] => 0 [log:protected] => Array ( ) [offset:protected] => 0 [sql:protected] => UPDATE #__content SET hits = hits + 1 WHERE id = 338 [tablePrefix:protected] => j25_ [utf:protected] => 1 [errorNum:protected] => 0 [errorMsg:protected] => [hasQuoted:protected] => [quoted:protected] => Array ( ) ) [name:protected] => article [option:protected] => com_content [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 338 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [event_clean_cache:protected] => onContentCleanCache [_errors:protected] => Array ( ) ) ) [_basePath:protected] => /home/hepqld/public_html/components/com_content [_defaultModel:protected] => article [_layout:protected] => default [_layoutExt:protected] => php [_layoutTemplate:protected] => _ [_path:protected] => Array ( [template] => Array ( [0] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/ [1] => /home/hepqld/public_html/components/com_content/views/article/tmpl/ ) [helper] => Array ( [0] => /home/hepqld/public_html/components/com_content/helpers/ ) ) [_template:protected] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/default.php [_output:protected] => [_escape:protected] => htmlspecialchars [_charset:protected] => UTF-8 [_errors:protected] => Array ( ) [baseurl] => [document] => JDocumentHTML Object ( [_links] => Array ( ) [_custom] => Array ( ) [template] => [baseurl] => [params] => [_file] => [_template:protected] => [_template_tags:protected] => Array ( ) [_caching:protected] => [title] => "Christmas comes early for Australians living with hepatitis C" - Hepatitis Australia [description] => Hepatitis Queensland [link] => [base] => http://www.hepqld.asn.au/news-media-a-events/our-news/3-news-a-events/338-christmas-comes-early-for-australians-living-with-hepatitis-c-hepatitis-australia [language] => en-gb [direction] => ltr [_generator] => Joomla! - Open Source Content Management [_mdate] => [_tab] => [_lineEnd] => [_charset] => utf-8 [_mime] => text/html [_namespace] => [_profile] => [_scripts] => Array ( [/media/system/js/mootools-core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/caption.js] => Array ( [mime] => text/javascript [defer] => [async] => ) ) [_script] => Array ( [text/javascript] => window.addEvent('load', function() { new JCaption('img.caption'); }); ) [_styleSheets] => Array ( ) [_style] => Array ( ) [_metaTags] => Array ( [http-equiv] => Array ( [content-type] => text/html ) [standard] => Array ( [keywords] => Hepatitis Queensland [rights] => [author] => Hepatitis Admin ) ) [_engine] => [_type] => html [_errors:protected] => Array ( ) ) [pageclass_sfx] => )

"Christmas comes early for Australians living with hepatitis C" - Hepatitis Australia

Smiley face
Image credit: Jane Little, in Sydney Morning Herald. Photo: Meredith O'Shea​


====================
UPDATE 22 December 2015: FAQs about the new hepatitis C medicines and the March 2016 PBS Listing
Click here to read the latest questions and answers:
http://www.hepatitisaustralia.com/faq-hep-c-treatments
====================


20 December 2015

LISTED!!!

We are very pleased to be able to share this special breaking news [now featured in Sydney Morning Herald].

We would like to thank each of you for your tremendous support and patience over such a long haul. This could not have happened without you.

There is still a long way to go and a great deal of work to be done but today is a day to remember.

We will continue to keep you updated as more details become available.

Thank you.

Regards
Clint Ferndale
CEO


Hepatitis Australia Media Release
For Immediate Release 20 December 2015

"Christmas comes early for Australians living with hepatitis C"



Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.

Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.

“Last week, we were incredibly disheartened that the Mid-Year Economic and Fiscal Outlook (MYEFO) announcement did not include funding for new hepatitis C medicines, but today we are overjoyed that the waiting is almost over,” Ms Tyrrell said.

“So many people have been anxiously waiting for this announcement. This is wonderful news and it is such a relief to have an end to the uncertainty,” she said.

“We congratulate Minister Ley who has delivered on her commitment to list these medicines as swiftly as she can and to make them available for everyone with hepatitis C, which hasn’t been achieved elsewhere.

“Christmas will be a particularly joyous time this year for many living with hepatitis C as they can now look forward to the prospect of a cure and a much healthier future,” Ms Tyrrell said.

“The Turnbull Government is to be congratulated for showing leadership and investing in these game-changing therapies which represent the greatest innovation in the treatment of the hepatitis C virus in a generation,” she said.

“If we can combine access to new treatments with improved access to needle and syringe programs across the country and in all populations, we have a real chance of preventing deaths and eliminating hepatitis C as a public health concern within a generation.

“We look forward to 2016 as the watershed year for hepatitis C in Australia as more people are treated and cured and we start to arrest spiralling rates of liver disease,” Ms Tyrrell added.

230,500 Australians are living with the hepatitis C virus which damages the liver, leading to liver scarring (cirrhosis), liver cancer and liver failure. Each month approximately 250 people with hepatitis C develop serious and potentially life-threatening liver disease or liver cancer.

New hepatitis C therapies have exceptionally high cure rates that exceed 90 per cent, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies.

“We urge all Australians with risk factors for hepatitis C to get tested and talk to their doctor about new treatments,” Ms Tyrrell concluded.

*sofosbuvir (Sovaldi); sofosbuvir and ledipasvir (Harvoni); daclatasvir (Daklinza) and ribavirin (Ibavyr).

Media Contact: Fiona Beveridge 0405 902 826.


Older news:

© copyright 2013 | All Rights Reserved | Website design Brisbane by iFactory